Novartis In-Licenses Dry-eye Drug to Challenge Shire and Allergan
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 5 (Table of Contents)
Published: 6 May-2017
DOI: 10.3833/pdr.v2017.i5.2243 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Novartis has elected to exercise an option granted to it in 2016 to in-license rights (excluding Europe) to ECF843 from Lubris BioPharma for ophthalmic indications, specifically for the treatment of dry eye...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS